Baird Reiterates Outperform Rating on Boston Scientific Despite Reduced Price Target
On May 19, Baird lowered its price target for Boston Scientific (NASDAQ:BSX) to $75 from $78 but maintained an 'Outperform' rating. The adjustment followed the company's re-entry into the TAVR market via a stake in MiRus and was cited as providing modest accretion.
